Founded in Manhattan in 2018, PhytoCell Biotech is advancing a next-generation biotechnology platform that combines synthetic biology, precision fermentation and advanced bioprocess engineering to enable consistent, scalable cannabinoid production. Our engineered microbial cell factories convert renewable feedstocks into high-purity CBD and other cannabinoids with consistent quality, scalable production and a more sustainable manufacturing footprint.
Traditional cannabinoid production depends heavily on agriculture, seasonal conditions and complex extraction. PhytoCell Biotech combines pathway design, strain engineering, controlled fermentation, analytical chemistry and downstream purification to produce traceable cannabinoid ingredients for pharmaceutical, nutraceutical, beauty, personal care and functional wellness partners.
We design microbial production systems that convert cells into reliable CBD-producing factories with controllable pathways and reproducible output.
Our bioprocess team optimizes media, feeding strategy, oxygen transfer and harvest timing to improve yield, consistency and scale-up readiness.
The same platform can be extended beyond CBD to support future research into differentiated cannabinoids and new product applications.
From early platform design to commercial-scale planning, PhytoCell Biotech has built its operating roadmap around technical validation, scale-up readiness and strategic collaboration.
PhytoCell Biotech was established in Manhattan to build a cannabinoid biomanufacturing platform based on synthetic biology and precision fermentation.
The company began pathway architecture work, strain selection and early process design for a microbial CBD cell-factory system.
Initial fermentation studies validated core production logic and strengthened the company’s bioprocess development workflow.
Pilot-scale readiness planning expanded across fermentation execution, analytics, quality systems and manufacturing documentation.
New strategic discussions and research collaborations supported broader platform relevance and long-range product optionality.
PhytoCell Biotech is advancing commercial-scale planning while refining its investor story, manufacturing strategy and partner-ready operating model.
Our scientific platform connects upstream biology with downstream process development. This integration is designed to create a disciplined pathway from microbial design to scalable, quality-controlled cannabinoid production.
Build and optimize engineered microbial hosts capable of expressing CBD biosynthesis pathways with stability and control.
Improve fermentation conditions, feeding strategies and operating parameters to drive repeatable CBD yield and manufacturability.
Develop downstream purification and analytical workflows that support product quality, process understanding and future commercialization.
Our scientific workflow links upstream biology, process development and downstream analytics into a single operating system that can support repeatable cannabinoid production.
Pathway logic, host selection and biosynthetic architecture are designed to support precision and controllability from the beginning.
The team optimizes precursor flow, enzyme coordination and pathway balance to improve target cannabinoid productivity.
Engineered microbial hosts act as programmable production systems capable of generating cannabinoids in a controlled environment.
Bioprocess conditions are tuned for consistency, scalability and strong operating discipline from laboratory work through pilot readiness.
Downstream purification, analytical methods and batch documentation help ensure high-purity outputs and decision-grade data.
Our pipeline is structured around four coordinated workstreams, from microbial strain design to pilot-ready fermentation and future cannabinoid exploration. The percentages below represent illustrative internal development readiness indicators.
Each program is designed to generate decision-quality data for scale-up, quality control and commercial translation. By integrating upstream biology with downstream process development, we can move faster with stronger operational discipline.
Request pipeline briefLead strain engineering program focused on robust microbial hosts, pathway integration and stable expression for direct CBD biosynthesis.
Metabolic pathway balancing program aimed at improving precursor flow, enzyme coordination and repeatable production efficiency.
Bioprocess development workstream covering media design, feed strategy, oxygen transfer and operating conditions for scale-ready performance.
Exploratory program extending the platform toward differentiated cannabinoids that could support future wellness, research and specialty applications.
Expanded pilot production capacity and strengthened the company-wide quality management system in preparation for larger-scale commercialization.
Signed new international research collaborations and introduced a higher-yield CBD production strain.
Advance commercial-scale manufacturing strategy while expanding the cannabinoid product development pipeline.
We are building PhytoCell Biotech around a simple idea: the future of cannabinoid manufacturing should be more predictable than agriculture alone. Our platform is designed to create technical leverage across product quality, scale-up execution and future cannabinoid development.
PhytoCell Biotech is building a differentiated cannabinoid platform centered on fermentation-derived CBD and future cannabinoid development. We see long-term value creation across ingredient supply, formulation partnerships, intellectual property licensing and strategic co-development opportunities.
Precision fermentation has the potential to reduce variability associated with plant extraction while supporting consistent output and greater manufacturing control.
Value is created through strain engineering, pathway design, bioprocess optimization and the know-how required to translate research into repeatable production.
The platform supports future opportunities in bulk ingredients, co-development, white-label applications, specialized formulations and strategic licensing.
Our operating model is designed to support collaboration with research groups, manufacturing partners, formulation teams and downstream commercial channels.
PhytoCell Biotech is developing a disciplined operating environment for fermentation execution, analytical quality control and scale-up planning. Our facility concept is designed to bridge laboratory science with dependable manufacturing practice.
Controlled bioreactor execution supporting media optimization, feeding strategy and process repeatability.
Analytical testing, purity verification and batch-level data review to support product confidence.
Documented workflows and process understanding built to support future expansion beyond laboratory scale.
Operational structure designed to support manufacturing partners, formulation teams and strategic collaborators.
PhytoCell Biotech’s leadership combines strategy, finance, synthetic biology, medical advisory, fermentation development and manufacturing execution to guide the company from platform innovation to partner-ready commercialization.
Founder of PhytoCell Biotech and architect of its long-range strategy. Vivian leads partnerships, capital planning and global business development across the platform.
Olivia oversees enterprise operations, corporate governance and milestone execution. She aligns research, quality, manufacturing and commercial teams around disciplined delivery.
Christina directs financial planning, treasury management and board reporting. She supports capital strategy, budgeting discipline and long-range value creation.
Dr. Chen leads platform science, strain design and translational R&D. His work spans synthetic biology, pathway engineering and differentiated product discovery.
A senior physician-scientist, Dr. Whitmore provides medical oversight, translational perspective and external scientific credibility across the platform.
Jennifer Doudna is one of the key pioneers of CRISPR gene-editing technology. Her research helped establish a transformative platform for modern genetics, and she received the 2020 Nobel Prize in Chemistry.
Katalin Karikó is a pioneering mRNA researcher whose decades of work laid critical foundations for the later development of mRNA vaccines. She was awarded the 2023 Nobel Prize in Physiology or Medicine.
George Church is a Harvard geneticist with major influence in genomics, synthetic biology, gene editing and anti-aging research. His work has helped shape the direction of advanced biological engineering.
Follow recent company developments across platform advancement, facility readiness, research progress and strategic collaboration supporting our CBD biosynthesis platform.
For partnerships, investment inquiries, media requests or business development discussions, contact our team. We welcome conversations with collaborators, platform partners and strategic stakeholders.
General inquiries
info@phytocellbiotech.com
Partnerships
partnerships@phytocellbiotech.com
Investor relations
investors@phytocellbiotech.com
Careers
careers@phytocellbiotech.com
Location
1271 6th Ave, New York, NY 10020